Search results
Showing 331 to 345 of 744 results for impact reports
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
User guide for the cost comparison company evidence submission template (PMG32)
This user guide describes how to submit evidence to NICE when a cost-comparison case is made as part of the fast track technology appraisal process. It explains what information NICE requires and the format in which it should be presented
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)
Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making
Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.
Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)
Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.
Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)
Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..
Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.
Early value assessment (EVA) guidance on digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments.
Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.
The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)
NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)
Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.
Artificial intelligence for analysing CT brain scans (MIB207)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .